Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems a...(will release three-year results fr...),Health

from the TAXUS V de novo (DN) clinical trial, evaluating the long-term

safety and clinical efficacy of the TAXUS Express2 Paclitaxel-Eluting

Coronary Stent System versus bare-metal stents in complex patient

populations, including small vessel lesions, long lesions, diabetics

and multiple stents. The TAXUS V DN trial is a prospective,

randomized, double-blind trial that has enrolled 1,172 patients at 66

sites in the U.S. The results will be presented by Stephen G. Ellis,

M.D., at an oral abstract session at 3:45 p.m. in Room 147AB.

-- TAXUS IV five-year results. The Company will release final five-year

data from the TAXUS IV clinical trial, which evaluates the TAXUS

Express2 Paclitaxel-Eluting Coronary Stent System versus bare-metal

stents. This prospective, randomized, double-blind study has enrolled

1,314 patients at 73 U.S. sites. The results will be presented by Dr.

Ellis at 4:00 p.m. at an oral abstract session in Room 147AB. The

Company plans to issue a press release at this time.

Tuesday, October 23

-- CABERNET & BEACH Trial Results on Carotid Stenting. At 4:00 p.m.,

three-year follow-up results from the CABERNET and BEACH clinical

trials will be presented in an oral abstract session by L. Nelson

Hopkins, M.D., in Room 147AB. The CABERNET trial was designed to

evaluate the safety and efficacy of the Company's NexStent(R) Carotid

Stent System and FilterWire EZ(TM) Embolic Protection System, which

received FDA approval in 2006. BEACH is a prospective, single-arm,

multi-center trial designed to evaluate similar clinical outcomes of

the Company's Monorail(R) Carotid WALLSTENT(R) Endoprosthesis in

conjunction with the FilterWire EX(R) and FilterWire EZ(TM) Embolic

Protection Systems in the tre
'/>"/>